$SMMT 在 HARMONi-GI1 研究中，晚期胆道癌患者接受 Ivonescimab 联合化疗的 OS 优于接受 Durvalumab 联合化疗。#ESMO26

与 Durvalumab 联合化疗相比，Ivonescimab 联合化疗将死亡风险降低 25%；OS 风险比为 0.75
https://www.businesswire.com/news/home/20261025603151/en/Ivonescimab-Plus-Chemotherapy-Demonstrates-Overall-Survival-Superiority-Compared-to-Durvalumab-Plus-Chemotherapy-in-First-Line-Treatment-of-Patients-with-Advanced-Biliary-Tract-Cancer-in-HARMONi-GI1-Study-Conducted-by-Akeso-in-China